VEA
NGM

Virtus ETF Advisers’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Virtus ETF Advisers’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18,916
Closed -$77.2K – 488
2023
Q1 		$77.2K Sell
18,916
-7,265
-28% -$33.6K 0.04% 389
2022
Q4 		$131K Buy
26,181
+17,854
+214% +$112K 0.07% 388
2022
Q3 		$109K Buy
8,327
+64
+0.8% +$969 0.04% 411
2022
Q2 		$106K Sell
8,263
-519
-6% -$7.19K 0.04% 418
2022
Q1 		$134K Sell
8,782
-519
-6% -$8.1K 0.06% 245
2021
Q4 		$165K Sell
9,301
-1,623
-15% -$31.1K 0.06% 311
2021
Q3 		$230K Sell
10,924
-577
-5% -$12.7K 0.1% 230
2021
Q2 		$227K Buy
11,501
+627
+6% +$14.7K 0.09% 257
2021
Q1 		$316K Buy
10,874
+189
+2% +$5.29K 0.13% 231
2020
Q4 		$324K Sell
10,685
-4,195
-28% -$91.8K 0.13% 190
2020
Q3 		$237K Sell
14,880
-2,033
-12% -$37.1K 0.12% 277
2020
Q2 		$334K Buy
+16,913
New +$323K 0.16% 283

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Virtus ETF Advisers's NGM Position: Q2 2023 in Review

Virtus ETF Advisers sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 18,916 shares — an estimated $77.2K sold.

Virtus ETF Advisers first reported a position in NGM in Q2 2020 and held it in 12 quarters. The position peaked at $334K in Q2 2020. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

  • Virtus ETF Advisers reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 18,916 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $77.2K.
  • Virtus ETF Advisers first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • Virtus ETF Advisers's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $334K in Q2 2020.
  • 106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.